Regorafenib (BAY 73-4506)

製品コードS1178 別名:Fluoro-Sorafenib

Regorafenib (BAY 73-4506)化学構造

分子量(MW):482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 27888.00
JPY 19920.00
JPY 34860.00
JPY 78020.00
JPY 161020.00

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
ターゲット
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
体外試験

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B MVLBdI9xfG:|aYOgRZN{[Xl? M{XqUFHjiJN3wrFOwG0> MXy0PEBp M3jqZ4lvcGmkaYTzJINmdGxiZ4Lve5Rp MVuyOlMzQTZyOB?=
PLC/PRF/5  Mlr0RZBweHSxc3nzJGF{e2G7 MXyx5qCUPcLizszN M2HhRlQ5KGh? MlnpbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4nBb|I3OzJ7NkC4
HepG2  M3W3SmFxd3C2b4Ppd{BCe3OjeR?= M1XkeFHjiJN3wrFOwG0> NEHiRm81QCCq MVTpcohq[mm2czDj[YxtKGe{b4f0bC=> MVGyOlMzQTZyOB?=
HEK293 M3v4dWZ2dmO2aX;uJGF{e2G7 NXjmZotqOC534pEJ{txO MV[yM|QwPiCq M3PXXpJm\HWlZYOgS3JRPzhiZYjwdoV{e2mxbh?= NWPydnZbOjV6NUiwN|I>
GEO NV31UJdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMlAyNTJyIN88US=> NWfDOHltQTZiaB?= MWrEUXNQ MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NID0N5ozPTh|OEO5NS=>
SW48 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSwMlAyNTJyIN88US=> MY[5OkBp NILnNFJFVVOR Ml;wbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHjuTowzPTh|OEO5NS=>
HT29 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXacGdoOC5yMT2yNEDPxE1? NIXBcHg6PiCq NInpOGZFVVOR NV\GOVB3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYfEZXE5OjV6M{izPVE>
SW480 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH2c3cxNjBzLUKwJO69VQ>? M3T2b|k3KGh? Mk\DSG1UVw>? MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlvQNlU5Ozh|OUG=
SW620 M3rq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfN[JIxNjBzLUKwJO69VQ>? NFH5XXY6PiCq NYLjN5lVTE2VTx?= M4jLPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoDhNlU5Ozh|OUG=
HCT116 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\LfWQxNjBzLUKwJO69VQ>? MX[5OkBp MnvrSG1UVw>? M1nrNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX7pOFRjOjV6M{izPVE>
LOVO NY\lWGd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHXNE4xOS1{MDFOwG0> M2nBSFk3KGh? MkH0SG1UVw>? MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXeyOVg{QDN7MR?=
HCT150 NWXHeWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkTYdCOC5yMT2yNEDPxE1? MV65OkBp NEjmUVVFVVOR NVr5RVlvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWOyOVg{QDN7MR?=
SW48-CR Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zvWVAvODFvMkCg{txO NHTUSZA6PiCq M2\0fmROW09? NGfSb3FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlH5NlU5Ozh|OUG=
GEO-CR MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXywMlAyNTJyIN88US=> Ml3aPVYhcA>? MW\EUXNQ NVO2WWV1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3uzeFI2QDN6M{mx
KB-31 NI\QdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LqdWlEPTB;NT61xtExNjNibl2= M3LBfFI2PzV|M{[x
KB-G2 NHnmOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3pTWM2OD17LkJCtVAvOSCwTR?= M4\vO|I2PzV|M{[x
LLC-PK1 M3rRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXjPJJtUUN3ME20Nk4xyrF|LkKgcm0> NHTRXYczPTd3M{O2NS=>
LLC-PK1/MRP2 NVHyXodIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTh{LkVCtVIvPyCwTR?= NH\1NVkzPTd3M{O2NS=>
HEK293 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7pTWM2OD1zMT6wxtEyNjJibl2= Mn3tNlU4PTN|NkG=
HEK293/OATP1B1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r2dGlEPTB;Nj6yxtExNjNibl2= MmrpNlU4PTN|NkG=
HROC18 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDoO3RKSzVyPUGuN{DPxE1? NFuzWHczPTNyOUmxOC=>
HROC24 NF\DVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInBdWpKSzVyPUSuOkDPxE1? MXyyOVMxQTlzNB?=
HROC43 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDvSVBwUUN3ME21MlMh|ryP MmS3NlU{ODl7MUS=
HROC46 M1XHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH3ZooxUUN3ME2yMlQh|ryP Ml2yNlU{ODl7MUS=
RJ345 NIm4VZRHfW6ldHnvckBCe3OjeR?= NWi1SJpsOC53L{Wg{txO MlPFNlQhcA>? NYLkTpdmTE2VTx?= NEXN[ZlqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NXXSfG9rOjV{NUO5PVQ>
RJ348 NWLiRWR5TnWwY4Tpc44hSXO|YYm= MmrhNE42NzVizszN MUCyOEBp NETNc4pFVVOR NGDXWZlqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> MX[yOVI2Ozl7NB?=
MCF-7 MlPSSpVv[3Srb36gRZN{[Xl? NIPERWcxNjVxNTFOwG0> MnraNlQhcA>? MlHKSG1UVw>? MXnpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= MkDSNlUzPTN7OUS=
MDA-MB-231 Mk\ESpVv[3Srb36gRZN{[Xl? NEHXbpUxNjVxNTFOwG0> NXvLd5hxOjRiaB?= M2L6UWROW09? MnjHbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u MUOyOVI2Ozl7NB?=
HT15 M3rtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLwNU0zOCEQvF2= M4r0ZVQ5KGh? MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVfXfIQ2OjVyN{GwNVg>
DLD1 NEHUOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX2NU0zOCEQvF2= NUnsb5ZWPDhiaB?= NGT0SYdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFvCR3ozPTB5MUCxPC=>
HT-29 NUXUeVFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjySnF{OS1{MDFOwG0> NV;EN5hlPDhiaB?= MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUCyOVA4OTBzOB?=
Hct-116 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixMVIxKM7:TR?= NWezfpFFPDhiaB?= M3;I[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYiyOVA4OTBzOB?=
HT15 MlzHRZBweHSxc3nzJGF{e2G7 MX[xMVExKM7:TR?= NGf3XVY1QCCq NVraOHBvcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mlv3NlUxPzFyMUi=
DLD1 NITrVGZCeG:ydH;zbZMhSXO|YYm= MlvzNU0yOCEQvF2= MYi0PEBp NXOzdVczcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVXkUnZEOjVyN{GwNVg>
HT-29 Mn3iRZBweHSxc3nzJGF{e2G7 NYrPfGdYOS1zMDFOwG0> NFLwWII1QCCq NXjNXYFbcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVSyOVA4OTBzOB?=
Hct-116 NGTDfFZCeG:ydH;zbZMhSXO|YYm= Mn\1NU0yOCEQvF2= MkLJOFghcA>? MkHRbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3nOZ|I2ODdzMEG4
GBM5 MWDBdI9xfG:|aYOgRZN{[Xl? NUHnN4o1OC534pETNU4x6oDLzszN MUiyOEBp NEnhN2hFVVOR NHPNPZpqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> M1LDeFI1QTFzMkG1
GBM6 NUHQ[W9sSXCxcITvd4l{KEG|c3H5 NViy[olDOC534pETNU4x6oDLzszN MlHUNlQhcA>? NFezZYFFVVOR MXzpcpRmemGldIOge4l1cCCuYYDheIlvcWJidH:gbY5lfWOnIHPlcIwh\GWjdHi= NYHtXHJ1OjR7MUGyNVU>
GBM12 M1X5[GFxd3C2b4Ppd{BCe3OjeR?= MUGwMlXjiJNzLkFihKnPxE1? MX2yOEBp M2jyTmROW09? M4LHeIlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> M4r1TVI1QTFzMkG1
GBM14  NWr0UHFVSXCxcITvd4l{KEG|c3H5 M13QXFAvPeLCk{GuNQKBkc7:TR?= MmLaNlQhcA>? MXTEUXNQ MX7pcpRmemGldIOge4l1cCCuYYDheIlvcWJidH:gbY5lfWOnIHPlcIwh\GWjdHi= M3y0dlI1QTFzMkG1
Hep3B NFTBO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYex5qCUOi53wrFOwG0> M{H0W|I1NzR6L{eyJIg> MX\pcohq[mm2czDj[YxtKGe{b4f0bC=> M{TYflI1QDh3OEmw
PLC/PRF/5  M1i0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPHNgKBmzJwNdMg{txO NVvq[YNFOjRxNEivO|IhcA>? NX\0RYo1cW6qaXLpeJMh[2WubDDndo94fGh? M2fVWFI1QDh3OEmw
HepG2  Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP4NgKBmzJwNdMg{txO NXnF[XRuOjRxNEivO|IhcA>? MX\pcohq[mm2czDj[YxtKGe{b4f0bC=> MmfNNlQ5QDV6OUC=
HCT116  NEfNN49HfW6ldHnvckBCe3OjeR?= NGLjdJoyOC9{MD:0NEDPxE1? Mn7UNlQhcA>? MYDpcoR2[2W|IGDVUWEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M3f0dFI1PzZ|NkGx
Lim2405 NUHKNXJGTnWwY4Tpc44hSXO|YYm= NVL1TIZFPDBizszN MXuyOEBp M1ixVolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NVG2d2lOOjR5NkO2NVE>
LoVo MUDGeY5kfGmxbjDBd5NigQ>? MnjJOFAh|ryP NGTOV3ozPCCq NHLj[4xqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MW[yOFc3OzZzMR?=
Lim1215 NW\Hd2s2TnWwY4Tpc44hSXO|YYm= NFu5PJQ1OCEQvF2= MkXVNlQhcA>? NHjGZmtqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MnrTNlQ4PjN4MUG=
SW48 M1zzSWZ2dmO2aX;uJGF{e2G7 NILJZ3k1OCEQvF2= MWOyOEBp NFzpcWxqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NGqwWlEzPDd4M{[xNS=>
RKO  M1\OcmZ2dmO2aX;uJGF{e2G7 MU[0NEDPxE1? NYDmbGE6OjRiaB?= MULpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M2jZ[|I1PzZ|NkGx
SW837 MnXtSpVv[3Srb36gRZN{[Xl? M2K3UVQxKM7:TR?= MY[yOEBp M{HxPYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MXqyOFc3OzZzMR?=
SW1463 NXP3PXkzTnWwY4Tpc44hSXO|YYm= MXu0NEDPxE1? NUfKUFJ6OjRiaB?= M1jleYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NXXK[FBEOjR5NkO2NVE>
SW480 MVvGeY5kfGmxbjDBd5NigQ>? NYnHTmE{PDBizszN NYXHZ2VTOjRiaB?= NHPJe|dqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MmrPNlQ4PjN4MUG=
Vaco432 NF62Vm1HfW6ldHnvckBCe3OjeR?= NH7MV|I1OCEQvF2= NE\SOVgzPCCq MWjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MXiyOFc3OzZzMR?=
Vaco400 NWi2SVk3TnWwY4Tpc44hSXO|YYm= NV7GWml2PDBizszN NVfxUm9ZOjRiaB?= NFHPZ25qdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MYqyOFc3OzZzMR?=
DLD1 NEjyR4hHfW6ldHnvckBCe3OjeR?= NUjlSnp4PDBizszN NXv4U4RyOjRiaB?= NH7nfJhqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? M2fOb|I1PzZ|NkGx
HT29  NFrueGdHfW6ldHnvckBCe3OjeR?= NYLL[485PDBizszN NI\h[mEzPCCq NVfU[ZNvcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MUGyOFc3OzZzMR?=
PLC/PRF/5  Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XrTFHjiJN3wsXN MXyyOE81QC95MjDo M2POdYlvcGmkaYTzJINmdGxiZ4Lve5Rp NHP6c2MzOzF4OUG0PC=>
HepG2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjTSWtjOeLCk{ZCuW0> NX3WWXd3OjRxNEivO|IhcA>? NGfwdVNqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NGPEUW0zOzF4OUG0PC=>
Hep3B  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPWNgKBmzYEtV2= MYmyOE81QC95MjDo NUfQd2IycW6qaXLpeJMh[2WubDDndo94fGh? NYnQbXpWOjNzNkmxOFg>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
細胞試験: [1]
+ 展開
  • 細胞株: GIST 882 and TT cells
  • 濃度: 5 nM-10 μM
  • 反応時間: 96 hours
  • 実験の流れ: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • 製剤: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • 投薬量: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 482.82
化学式

C21H15ClF4N4O3

CAS No. 755037-03-7
保管
別名 Fluoro-Sorafenib

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VEGFRシグナル伝達経路

VEGFR Inhibitors with Unique Features

相関VEGFR製品

Tags: Regorafenib (BAY 73-4506)を買う | Regorafenib (BAY 73-4506) ic50 | Regorafenib (BAY 73-4506)供給者 | Regorafenib (BAY 73-4506)を購入する | Regorafenib (BAY 73-4506)費用 | Regorafenib (BAY 73-4506)生産者 | オーダーRegorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506)化学構造 | Regorafenib (BAY 73-4506)分子量 | Regorafenib (BAY 73-4506)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID